TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00470223
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00596336
Drug: influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: trispecific influenza vaccine 0.5 ml subcutaneously
Study: NCT01673529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match SB705498 will be used in both Part A and Part B of the study.
Study: NCT02670109
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 80mg/kg, IV, in 2 hours, during two days -2, -3
Study: NCT00409838
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, ≥ 15 mg, weekly, 6 months
Study: NCT00409838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
Study: NCT02055976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
Study: NCT02055976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Q14D SC for 16 week
Study: NCT00409838
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, oral, 15 mg weekly to be adjusted according to patient condition
Study: NCT00972049
Drug: AZD2516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered once orally. Specific dose depends on dose panel.
Study: NCT00972049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered once orally
Study: NCT00186849
Drug: Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for details of treatment interventions.
Study: NCT05021666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00633477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
Study: NCT02022059
Drug: Group B placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
Study: NCT00100698
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneously once a day, 18 months
Study: NCT01426412
Drug: LY3015014 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV over 30-90 minutes
Study: NCT04337879
Drug: AL2846
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
Study: NCT04337879
Drug: Calcium folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
Study: NCT00313742
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01426412
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV only over 30-90 minutes
Study: NCT01439789
Drug: rhNRG-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study: NCT01439789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study: NCT01766050
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03895515
Drug: Fiasp®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.
Study: NCT03452397
Drug: 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
Study: NCT04239001
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, patients with pancreatic cancer who met the input / discharge criteria were given secondary prophylactic administration of the tested drug PEG-rhG-CSF.
Study: NCT03525444
Drug: VX-445/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received VX-445/TEZ/IVA orally once daily in the morning.
Study: NCT03525444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched VX-445/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
Study: NCT03452397
Drug: 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
Study: NCT03744910
Drug: Physiologic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT02973100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03818100
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy will commence following completion of radiotherapy, and will continue for 20 weeks.
Study: NCT02942862
Drug: Orcein staining
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prognostic value of venous emboli detected by orcein staining
Study: NCT03037892
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The group 3 patient will receive only Remifentanil in the same doses as given in group
Study: NCT02892214
Drug: estriol cream (ovestin)
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00971724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, once daily, for 15 days
Study: NCT00971724
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02814838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT03767452
Drug: Xiaflex® 0.58 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mL injections.
Study: NCT02229721
Drug: Syntocinon Nasalspray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly.
Study: NCT01751269
Drug: RPX7009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
Study: NCT01751269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
Study: NCT02229721
Drug: Placebo Nasalspray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly.
Study: NCT00220519
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00704314
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg Simvastatin daily for 8 weeks
Study: NCT00704314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo was identical in appearance and was provided by the same manufacturer
Study: NCT00662519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
Study: NCT04846829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
Study: NCT02161770
Drug: AZD9291 tablet dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
Study: NCT00517673
Drug: GSK945237
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02809989
Drug: Ovaleap®
Approvals — FDA: no, EMA: no, PMDA: no
Description: About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births).
Study: NCT03514836
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: immunomodulatory medication given around the ONCOS-102 dosing
Study: NCT02253459
Drug: UTD1 Injection plus capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02253459
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01230827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
Study: NCT01230827
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
Study: NCT00879333
Drug: Best Supportive Care (BSC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
Study: NCT03571230
Drug: one proton pump inhibitor(PPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients need this drug.
Study: NCT02430298
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
Study: NCT02430298
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
Study: NCT01521494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04418908
Drug: Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release
Normalized name: Estradiol Patch, 0.025 mg/24 hours weekly transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active estradiol transdermal patch.
Study: NCT04418908
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch designed to match active Climara patches.
Study: NCT00882440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule to losartan
Study: NCT04683627
Drug: Diclofenac sodium active topical patch
Normalized name: diclofenac sodium Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.
Study: NCT04683627
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo patch without diclofenac sodium was used for the placebo arm.
Study: NCT00424463
Drug: MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
Study: NCT03396900
Drug: RhBMP-2 Protein, Recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
Study: NCT04649541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose in water
Study: NCT04218266
Drug: BAY2433334
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, taken orally once a day.
Study: NCT01935622
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 1 tablet every 12 hours for 14 days
Study: NCT01935622
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet every 12 hours for 14 days
Study: NCT01927640
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (10 cc)
Study: NCT03524846
Drug: Ascorbic Acid 300 MG
Normalized name: ascorbic acid 300 MG
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
Study: NCT03435666
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
Study: NCT03524846
Drug: Ascorbic Acid 600 MG
Normalized name: ascorbic acid 600 MG
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
Study: NCT03524846
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
Study: NCT03852602
Drug: Preemptive Analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic application15 minutes before the treatment
Study: NCT00570089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
Study: NCT00002494
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01351103
Drug: LGK974
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002494
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002494
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002494
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002494
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02592031
Drug: XM17
Normalized name: Ximelagatran
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IU corresponds to an injection volume of 0.5 mL.
Study: NCT01749930
Drug: BOL-303259-X
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
Study: NCT02592031
Drug: Gonal-f®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IU corresponds to an injection volume of 0.5 mL.
Study: NCT02592031
Drug: Zoladex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mg
Study: NCT01749930
Drug: BOL-303259-X
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
Study: NCT01327924
Drug: Norditropin NordiFlex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
Study: NCT02057939
Drug: Androgen Deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
Study: NCT02709850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9%NaCl, water, riboflavin
Study: NCT00510406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01872078
Drug: AZD4901 (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Study: NCT04377308
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration
Study: NCT00600639
Drug: standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
Study: NCT00600639
Drug: standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxygen plus medical therapy for ARF
Study: NCT02119650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg matching placebo tablets to be administered by mouth
Study: NCT04497766
Drug: Nebulized Magnesium sulfate
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes
Study: NCT04497766
Drug: Intravenous magnesium sulphate
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
Study: NCT02824458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03770689
Drug: Peposertib 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
Study: NCT03770689
Drug: Peposertib 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
Study: NCT03770689
Drug: Peposertib 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
Study: NCT03770689
Drug: Peposertib 250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
Study: NCT03770689
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.
Study: NCT02269475
Drug: MEDI3250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI3250
Study: NCT02269475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04758416
Drug: 68Ga-HER2 affibody,18F-FDG, 18F-FES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
Study: NCT03387670
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * One (1 = 40mg) simvastatin tablet once daily at night for 1 month~* Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 to 53 months
Study: NCT03387670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * One (1) placebo tablet once daily at night for 1 month~* Two (2) placebo tablets once daily at night, for the next 35 to 53 months
Study: NCT03040999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline or dextrose solution administered as an IV infusion Q3W
Study: NCT01901809
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02253914
Drug: BILR 355 BS, solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253914
Drug: BILR 355 BS, tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00645034
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo by mouth as a single dose